This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
AL amyloid deposit confirmed by biopsy and IHC or mass spectrometry
Amyloid deposits are measurable by imaging (ultrasound or cross-sectional)
18 years or older
ECOG performance status 0-3
Use of other investigational agents within 30 days of screening
Taking doxycycline within 30 days of screening
Current significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders, or psychiatric disorder.
Major surgery within 4 weeks of enrollment